September 2017 issue
August 2017 issue
July 2017 issue
June 2017 issue
May 2017 issue
April 1, 2017 issue
March 2017 issue
February 2017 issue
January 2017 issue
December 2016 Issue
Peace and Good Will
New Drug Review: Lixisenatide (Adlyxin – Sanofi)
Index for Volume 11, 2016
November 2016 Issue
Feature: You Say Adherence and I Say Compliance – Whatever We Call It, Pharmacists, with Our Patients, Must Respond to this Challenge!
New Drug Review: Lifitegrast (Xiidra – Shire)
October 2016 Issue
Feature: Understanding and Reducing Drug Prices Must Start with Transparency
New Drug Review: Insulin degludec (Tresiba – Novo Nordisk)
September 2016 Issue
Feature: Our Profession and Our Patients Need Independent Pharmacists! But Can We Keep Them?
August 2016 Issue
Feature: The PBM Formulary Follies
New Drug Review: Pimavanserin tartrate (Nuplazid – Acadia)
July 2016 Issue
Feature: CVS has an Exceptional Opportunity but Rejects It – To the Peril of its Customers and Frustration and Risk of its Pharmacists!
New Drug Review: Brivaracetam (Briviact – UCB)
June 2016 Issue
Feature: Physician-Assisted Suicide - Can we not care best for our patients by walking with them in the dying instead of leading them to it?
New Therapeutic Agents Marketed in the United States in 2015
May 2016 Issue
Feature: OUTRAGES! – But Some With Opportunities!
New Drug Review: Lesinurad (Zurampic – AstraZeneca; Ironwood)
April 2016 Issue
Feature: The FDA Should Provide Pharmacists with the Authority to Dispense Chantix Without a Prescription
New Drug Review: Cariprazine hydrochloride (Vraylar – Allergan)
March 2016 Issue
Feature: Prescription Drug Prices – Billions for Pharmaceutical Companies, Insurance Companies, and PBMs, but Pennies for Pharmacies
New Drug Review: Eluxadoline (Viberzi – Allergan)
February 2016 Issue
Feature: Is Walgreens Valeant's New Philidor?
New Drug Review: Mepolizumab (Nucala – GlaxoSmithKline)
January 2016 Issue
Feature: Pharmacy Must Have a More Effective Organizational Structure! - The United Pharmacists of America
New Drug Review: Ledipasvir/sofosbuvir (Harvoni – Gilead Sciences)
New Drug Review: Secukinumab (Cosentyx – Novartis)